Taking drug development to the next level
BioCopy works on future tumor and autoimmune therapeutics.
With our cutting-edge platform technology, we put immune profiling and lead screening of future immunotherapeutics on the next level.
Fast and effective
At BioCopy, we are fast an effective when it comes to identifying lead candidates for TCR-based cancer therapeutics.
With our technology and expertise, we simultaneously analyze interactions of TCR, bi- and multispecifics, and other biomolecules for binding against thousands of peptide-HLA complexes. With our proprietary microarray platform, we investigate thousands of interactions with peptide-HLA in parallel, within a single measurement. This provides us with a wealth of binding kinetic data.
With the novel, patented screening technology, BioCopy will accelerate and improve the development of immunotherapeutics. It is one of the few companies worldwide who can support targeted therapy development for both pathways (B-cell and T-cells) of the immune system. |
Rainer BöhmFormer Chief Commercial and Medical Affairs Officer at Novartis Pharma and Member of the Board of Directors at BioCopy |